Journal: Journal of Primary Care & Community Health

Article Title: Determination of COVID-19 Late Disorders as Possible Long-COVID and/or Vaccination Consequences

doi: 10.1177/21501319241251941

Figure Lengend Snippet: The Clinical Characteristics of Vaccinated Cases Against COVID-19 With Persistent Complications.

Article Snippet: 21 , Female , 42 , 29.1 , Menstrual , AstraZeneca/PastoCovac plus , Post the second dose , 180 , — , 7 months before vaccination , ✓ , —.

Techniques: Injection, Muscles

Journal: Journal of Primary Care & Community Health

Article Title: Determination of COVID-19 Late Disorders as Possible Long-COVID and/or Vaccination Consequences

doi: 10.1177/21501319241251941

Figure Lengend Snippet: Characterization of persistent symptoms post COVID-19 vaccination/infection. Totally 44 complications were recorded in 41 individuals post COVID-19 and/or vaccination. Three individuals had more than 1 complication and the rate of the disorders indicate the high prevalence of menstrual disturbances and hair loss following joints and muscles involvements.

Article Snippet: 21 , Female , 42 , 29.1 , Menstrual , AstraZeneca/PastoCovac plus , Post the second dose , 180 , — , 7 months before vaccination , ✓ , —.

Techniques: Infection, Muscles

Journal: NPJ Vaccines

Article Title: Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates

doi: 10.1038/s41541-022-00436-6

Figure Lengend Snippet: a Study design. African green monkey NHP were vaccinated with COH04S1 vaccine using two-dose (COH04S1-2D; n = 6) or single-dose (COH04S1-1D; n = 6) vaccination regimens as indicated. Mock-vaccinated NHP ( n = 3) and NHP vaccinated with empty sMVA vector using the same dose vaccination regimens ( n = 3) were included as controls. Six weeks after immunization, NHP were IN/IT challenged with SARS-CoV-2 USA-WA1/2020 reference strain. Bronchoalveolar lavages (BAL) and oral and nasal swab samples for viral load analysis were collected at multiple time points post-challenge. A subset of animals in each group were necropsied at day 7 and 21 post-challenge for viral load and histopathology analysis. b – d Binding antibody titers. S, RBD, and N antigen-specific binding antibody titers were measured at the indicated time points in serum samples of COH04S1-2D and COH04S1-1D-vaccinated NHP via ELISA. Data is presented as geometric mean values ± geometric s.d. Two-way ANOVA followed by Sidak’s multiple comparison test was used. e VOC-specific antibody titers. S-specific binding antibody titers were measured at day 62 by ELISA using S antigens based on the Wuhan-Hu-1 reference strain or several SARS-CoV-2 VOC, including Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2). Endpoint titers are presented as geometric mean values ± geometric s.d. Two-way ANOVA with Sidak’s multiple comparison test was used for statistical analysis. f BAL antibody titers. S, RBD, and N antigen-specific binding antibody titers were measured by ELISA at day 42 in BAL samples of COH04S1-IM and COH04S1-IN vaccine group. Endpoint titers are presented as geometric mean values ± geometric s.d. Two-way ANOVA with Sidak’s multiple comparison test was used. g NAb titers. NAb titers were measured by PRNT assay against SARS-CoV-2 infectious virus in serum samples of COH04S1-vaccinated NHP. Serum dilutions reducing the plaque number by 50% (ID50) are presented as geometric mean values ± geometric s.d. Two-way ANOVA followed by Sidak’s multiple comparison test was used to compare ID50 values. PRNT-assayed NAb titers measured in serum samples of healthcare workers ( N = 14) vaccinated two times with Pfizer-BioNTech BNT162b2 mRNA vaccine were included. Dotted lines in b – g indicate the lower limit of detection. Green and purple triangles indicate the time of vaccination. Red triangles indicate time of pre-challenge sampling. h – i T cell responses. IFNγ-, IL-2-, and IL-4-expressing S- and N-antigen-specific T cell responses were measured at day 42 by ELISPOT. Bars represent mean values, lines represent ± s.d. Two-way ANOVA followed by Tukey’s multiple comparison test was used. Dotted lines indicate the arbitrary positive threshold of 30 spots/10 6 cells. *0.05 < p < 0.01, **0.01 < p < 0.001, ***0.001 < p < 0.0001, **** p < 0.0001.

Article Snippet: Notably, NAb measured by PRNT assay in COH04S1-2D- and COH04S1-1D-vaccinated NHP were within the range of peak titers measured post-second dose in a cohort of healthcare workers that received the FDA-approved BNT162b2 mRNA vaccine from Pfizer/BioNTech.

Techniques: Plasmid Preparation, Histopathology, Binding Assay, Enzyme-linked Immunosorbent Assay, Comparison, Plaque Reduction Neutralization Test, Virus, Sampling, Expressing, Enzyme-linked Immunospot

Journal: International Journal of Infectious Diseases

Article Title: Side effects and perceptions following Sinopharm COVID-19 vaccination

doi: 10.1016/j.ijid.2021.08.013

Figure Lengend Snippet: Reasons for participants not receiving the COVID 19 vaccine

Article Snippet: This study showed that first and second dose post-vaccination adverse reactions of Sinopharm COVID-19 vaccine were common side effects that were mild, predictable, non-serious and non-life-threatening.

Techniques: